$35.45
▲ +1.5% Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
3 Reasons Why Growth Investors Shouldn't Overlook Indivior Pharmaceuticals Inc. (INDV)
Overview
52-week range
$22
$43
64% of range
Avg surprise (last 2)
+91.3%
Avg reaction (last 1)
+13.9%
100% positive
Latest IV / EM
62%
EM ±9.7% · $35 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.98 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $0.69 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.33 | — | — | — | — | financials |
| Thu Jul 31, 2025 | Jun/2025 | $0.51 | $0.26 | +96.2% | — | — | earnings |
| Thu Apr 24, 2025 | Mar/2025 | $0.41 | $0.22 | +86.4% | — | +13.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.72 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.45 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $343M | $317M | — | $314M | $302M | $266M | — | $307M |
| Cost of revenue | $50M | $40M | — | $83M | $52M | $44M | — | $66M |
| Gross profit | $294M | $277M | — | $230M | $250M | $221M | — | $241M |
| Operating income | $160M | $137M | — | $43M | $72M | $66M | $46M | — |
| Net income | $122M | $89M | — | $42M | $18M | $47M | $21M | — |
| EPS (diluted) | $0.98 | $0.69 | — | $0.33 | $0.14 | $0.38 | — | $0.16 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $222M | $175M | $195M | $445M | $510M | $372M | $319M | — |
| Inventory | $150M | $152M | $153M | $155M | $149M | $163M | $167M | — |
| Total current assets | $725M | $667M | $652M | $922M | $951M | $883M | $827M | — |
| Total assets | $1.23B | $1.20B | $1.20B | $1.42B | $1.45B | $1.38B | $1.32B | — |
| Long-term debt | $487M | $486M | $290M | $304M | $308M | $311M | $315M | — |
| Total liabilities | $1.44B | $1.34B | $1.30B | $1.62B | $1.71B | $1.66B | $1.65B | — |
| Total equity | $-208M | $-144M | $-98M | $-207M | $-257M | $-285M | $-337M | $-310M |